Perhaps most excitingly, our work suggests that combining an anti-GDF15 antibody with chemotherapy could improve the overall survival of patients by the dual mechanisms of decreasing cachexia and either killing or preventing the development of DTPs during chemotherapy. This evidence concerns the gene GDF15 and Cachexia.